Simplify Logo

Full-Time

Scientist II

Computational Biology

Confirmed live in the last 24 hours

Verve Therapeutics

Verve Therapeutics

201-500 employees

Developing gene editing therapies for heart disease

Biotechnology
Healthcare

Senior, Expert

Boston, MA, USA

Hybrid role requiring 3 days in the Boston office.

Category
Computational Biology
Biology & Biotech
Required Skills
Python
R
Data Analysis
Requirements
  • Ph.D. in computational biology, systems biology, bioinformatics or related fields with 2+ years of relevant industry experience or;
  • M.S. in computational biology, systems biology, bioinformatics or related fields with 7+ years of relevant industry experience or;
  • B.S. in computational biology, systems biology, bioinformatics or related fields with 9+ years of relevant industry experience.
  • In depth knowledge of in NGS data analysis, e.g., for targeted amplicon sequencing, genome-wide sequencing, variant calling.
  • Working knowledge of commonly used statistical approaches.
  • Proficient in Python and/or R programming languages.
  • Proven experience with tools and frameworks for reproducible scientific research, demonstrated by a strong publication record reflecting relevant research expertise.
  • Proven ability to thrive in a collaborative team setting, formulating research questions, developing methodologies, and analyzing and interpreting results.
  • Exceptional analytical and problem-solving skills, with strong communication and interpersonal abilities.
  • Collaborative, detail-oriented mindset, adept at efficiently working across multiple teams and projects in a matrixed environment.
Responsibilities
  • Perform data analysis of gene editing outcomes using state-of-the-art methods and tools.
  • Collaborate with cross-functional teams providing input to the experimental design and data interpretation.
  • Develop novel methods for NGS-based on- and off-target analysis, and high-throughput screens, incorporating appropriate statistical analyses as needed.
  • Coordinate activities and timelines through close collaboration with the laboratory head and other staff
  • Effectively communicate analysis results to key technical and non-technical stakeholders.
  • Maintain scientific and technical expertise through familiarity with scientific literature.
  • Mentor junior team members.
  • Research and evaluate new methods and technologies for continual process improvement with the goal of developing robust and scalable processes.
  • Ensure effective, high quality, timely and appropriate documentation. Recording, analyzing, and documenting data and results appropriately.
  • Interpret data, documents, study results and presentation of data and conclusions to diverse function groups. May author development reports, study protocols and pre-validation reports.
  • Troubleshoot scientific and technical challenges and contribute to their resolution.
  • Other duties as assigned.

Verve Therapeutics is developing single-course gene editing medicines to address cardiovascular disease, with a focus on precision genetic editing technologies to lower LDL cholesterol and triglyceride levels. Their lead program, VERVE-101, targets heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Company Stage

IPO

Total Funding

$419.3M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

4%

1 year growth

5%

2 year growth

33%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant financial backing, including a $63 million Series A2 financing and $60 million from Eli Lilly, positions Verve for robust R&D and clinical trial activities.
  • The potential for a 'one-and-done' treatment for cardiovascular diseases could revolutionize the field and offer a high-impact, life-saving solution.
  • Early-stage success and strategic partnerships could lead to lucrative licensing deals and further investment opportunities.

What critics are saying

  • The clinical-stage nature of Verve's therapies means they are still years away from potential market approval, posing a long-term risk.
  • The recent stock price drop following a public offering indicates market volatility and potential investor uncertainty.

What makes Verve Therapeutics unique

  • Verve Therapeutics focuses on gene-editing therapies specifically for cardiovascular diseases, setting it apart from other CRISPR-based companies that target a broader range of conditions.
  • Their 'one-and-done' gene-editing approach aims to provide a single, curative treatment, which is a significant advantage over traditional, ongoing therapies.
  • Partnerships with major pharmaceutical companies like Eli Lilly enhance their credibility and provide substantial financial and research support.